14
Treatment
Summary of Recommendations
Recommendation # Description
10.1
10.2
For patients with stage IV NSCLC and MET exon 14 skipping
mutation
• In the second-line setting, for MET abnormalities other
than exon 14 skipping mutations or if MET-targeted
therapy was given in the first-line setting, standard
treatment based on the ASCO/OH non-driver mutation
guideline should be offered (Moderate recommendation:
IC-L).
• In the second-line setting, patients with a MET exon
14 skipping mutation who previously received or were
ineligible for first-line chemotherapy with or without
immunotherapy (i.e., if MET-targeted therapy was not
given in the first-line setting ), capmatinib or tepotinib may
be offered (Moderate recommendation: IC-L).
11.1
11.2
For patients with stage IV NSCLC and driver alterations in RET
• In the first-line setting, selpercatinib or pralsetinib may be
offered (Weak recommendation: IC-L).
• In the first-line setting, standard therapy following the
non-driver mutation guideline may be offered (Moderate
recommendation: IC-L).
12.1
12.2
For patients with stage IV NSCLC and driver alterations in RET
• In the second-line setting, if RET-targeted therapy was
given in the first-line setting, standard treatment per the
non-driver mutation guideline may be offered (Moderate
recommendation: IC-L).
• In the second-line setting, if RET-targeted therapy was not
given in the first-line setting, selpercatinib may be offered
(Moderate recommendation: IC-L) or pralsetinib may be
offered (Weak recommendation: IC-L).
(cont'd)
